Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversibly binding P2Y12 platelet inhibitor. It is part of a class of drugs known as antiplatelet agents.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of thrombotic cardiovascular events, in combination with aspirin, in patients with ACS.
* **Myocardial Infarction (MI):** In patients with a history of MI, ticagrelor is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke among patients at high risk for events, supported by evidence from clinical trials in patients with prior MI.
## Adult Dosing
* **ACS:** 180 mg orally once, followed by 90 mg orally twice daily.
* **History of MI:** 60 mg orally twice daily.
* **Loading Dose:** A 180 mg loading dose is recommended upon initiation for ACS.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Safety and efficacy have not been studied in patients with severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is necessary in patients with mild to moderate renal impairment. In patients with severe renal impairment, consider the potential benefits and risks, as ticagrelor is cleared by the kidneys.
## Contraindications
* **Active Bleeding:** Patients with active pathological bleeding or a history of intracranial hemorrhage.
* **Hypersensitivity:** Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Bleeding:** The most common and serious adverse effect is bleeding, including life-threatening and fatal bleeding. This can manifest as bruising, epistaxis, hematuria, gastrointestinal bleeding, and intracranial hemorrhage.
* **Dyspnea:** Shortness of breath is a common side effect.
* **Bradycardia:** Can occur, especially in patients taking other medications that cause bradycardia.
* **Hyperuricemia and Gout:** Ticagrelor can increase uric acid levels.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor concentrations. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor concentrations.
* **Other Antiplatelet Agents/Anticoagulants:** Increased risk of bleeding. Use with caution and monitor closely.
* **Statins:** Increased AUC of rosuvastatin and simvastatin. Monitor for statin-related adverse effects.
* **Omeprazole:** Coadministration with omeprazole reduces ticagrelor exposure. The clinical significance is uncertain, but consider the timing of administration.
* **Dose-Dependent Effects:** Avoid concomitant use of ticagrelor with aspirin doses >100 mg if used for secondary prevention of MI.
## Monitoring
* **Bleeding:** Closely monitor patients for any signs or symptoms of bleeding.
* **Renal and Hepatic Function:** Monitor periodically, especially in patients with pre-existing impairment.
* **Uric Acid Levels:** Monitor periodically, particularly in patients with a history of gout or hyperuricemia.
## Clinical Pearls
* Ticagrelor is a P2Y12 inhibitor that is dosed twice daily, unlike clopidogrel and prasugrel.
* The maintenance dose for patients with a history of MI is 60 mg twice daily.
* Discontinuation of ticagrelor, especially within the first year after ACS, may increase the risk of thrombotic events.
* The decision to continue or discontinue ticagrelor should be individualized based on the patient's risk of bleeding and ischemic events.
* Patients experiencing dyspnea should be evaluated for underlying causes, but if no other cause is identified, ticagrelor may be continued if benefits outweigh risks.
This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive patient management decisions.
